Is There a Rationale for Angiotensin Blockade in the Management of Obesity Hypertension?

Hypertension - Tập 44 Số 1 - Trang 12-19 - 2004
Arya M. Sharma1
1McMaster University, Hamilton General Hospital, 237 Barton Street East, Hamilton, ON, Canada.

Tóm tắt

Obesity, currently affecting >20% of the adult population in most Western countries, is a major risk factor for the development of hypertension. Hypertension in obese patients is, in the majority of instances, further complicated by the concomitant presence of dyslipidemia and insulin resistance. The latter is reflected by derangement of glucose homeostasis, ranging from hyperinsulinemia to frank type 2 diabetes. Hypertension in obese patients is also associated with an increased risk for left ventricular hypertrophy, endothelial dysfunction, renal hyperfiltration, microalbuminuria, and elevated markers of inflammation. Sodium retention, volume expansion, and increased cardiac output are common findings in obese individuals. These changes are largely attributable to increased activity of the sympathetic nervous system and insufficient suppression of the renin-angiotensin system. Recent data show increased expression of angiotensin II–forming enzymes in adipose tissue, and increased activity of the renin-angiotensin system has recently been implicated in the development of insulin resistance and type 2 diabetes. Accordingly, antihypertensive agents that block the renin-angiotensin system might be a beneficial strategy for treatment of obesity-related hypertension. Both angiotensin-converting enzyme inhibitors and angiotensin type-1 receptor blockers have been associated with favorable metabolic properties and end-organ protection in addition to their antihypertensive effects. Data from ongoing large trials will provide an indication of the protective and preventive effects of these treatment strategies while offering insights into the mechanisms linking obesity, hypertension, and other facets of the metabolic syndrome.

Từ khóa


Tài liệu tham khảo

10.1001/jama.288.14.1758

10.1001/archinte.159.18.2177

10.1007/s11892-003-0057-2

10.1161/01.CIR.0000088845.17586.EC

10.1007/s11892-003-0059-0

10.1007/s11892-003-0058-1

10.1161/01.hyp.23.1_suppl.i20

10.1016/S0895-7061(97)00075-7

10.1161/01.hyp.0000052314.95497.78

10.1152/ajpendo.1996.270.2.E363

10.1161/hyp.38.3.379

10.1161/01.hyp.0000098660.26184.63

10.1161/hyp.25.4.893

10.1161/hyp.25.4.834

10.1161/hyp.35.1.403

10.1016/S0895-7061(01)02077-5

10.1161/hyp.33.1.537

10.1038/380677a0

10.1152/ajpendo.00259.2003

10.1172/JCI119532

10.1161/hyp.31.1.409

10.1172/JCI8341

10.1056/NEJM199602013340503

10.1097/00004872-199816121-00023

10.1097/00004872-199816100-00011

10.1097/00004872-199917100-00013

10.2337/diab.45.7.988

10.1016/S0002-9149(97)00832-1

10.1007/s001090000144

10.1161/hyp.33.1.548

10.1161/01.hyp.0000113047.47711.fa

10.1055/s-2007-978675

10.1038/sj.ijo.0801082

10.1161/circ.95.10.2348

10.1161/hyp.32.5.875

Jones BH, Standridge MK, Taylor JW, Moustaid N. Angiotensinogen gene expression in adipose tissue: analysis of obese models and hormonal and nutritional control. Am J Physiol. 1997; 273: R236–R242.

10.1016/S0925-4439(99)00091-5

10.1096/fj.01-0457fje

10.1111/j.1749-6632.1999.tb07791.x

Cassis LA, English VL, Bharadwaj K, Boustany CM. Differential effects of local versus systemic angiotensin II in the regulation of leptin release from adipocytes. Endocrinol. 2004; 145: 196–174.

Darimont C, Vassaux G, Gaillard D, Ailhaud G, Negrel R. In situ microdialysis of prostaglandins in adipose tissue: stimulation of prostacyclin release by angiotensin II. Int J Obes Relat Metab Disord. 1994; 18: 783–788.

10.1210/endo.135.5.7956925

10.2337/diabetes.51.6.1699

10.1210/endo.138.4.5038

10.1016/S1097-2765(00)80210-5

10.1161/01.hyp.0000042665.85720.a0

10.1161/01.hyp.0000036448.44066.53

10.1042/bj3570899

10.1161/01.HYP.0000110061.06674.ca

10.1006/bbrc.1999.0255

10.1055/s-2007-978586

10.1161/circ.100.25.2473

10.1038/90984

10.1161/01.cir.0000042707.50032.19

10.1152/ajpendo.00110.2003

10.1016/S1359-6101(03)00052-2

10.2337/diabetes.52.4.942

10.1161/01.hyp.0000078490.59735.6e

10.1097/01.ASN.0000070146.29445.D8

10.1161/01.hyp.22.3.292

10.1016/S0272-6386(03)00020-9

10.1046/j.1464-5491.2002.00806.x

10.1161/hyp.26.4.610

10.1016/S0895-7061(00)01254-1

10.1046/j.1523-1755.2001.0590041498.x

10.1681/ASN.V10112382

Kasiske BL, Cleary MP, O’Donnell MP, Keane WF. Effects of genetic obesity on renal structure and function in the Zucker rat. II. Micropuncture studies. J Lab Clin Med. 1985; 106: 598–604.

10.1161/01.hyp.19.1_suppl.i110

10.1161/hyp.28.6.1047

10.1093/jn/131.3.913S

10.1161/01.hyp.21.6.1039

10.1161/hyp.35.4.1009

10.1046/j.1523-1755.2000.00218.x

10.1161/hyp.25.4.888

10.1007/s11906-002-0064-8

10.1161/01.HYP.0000107251.49515.c2

10.1097/00004872-200104000-00001

10.1161/hyp.37.2.250

10.1161/01.hyp.0000116223.97436.e5

10.1093/ndt/17.3.353

10.1016/S0033-0620(99)70022-8

Am Diabetes Association. Treatment of hypertension in adults with diabetes. Diabetes Care. 2003; 25: S71–S73.

10.1097/00004872-200205000-00032

10.1016/S0002-9149(01)02322-0

Sanchez RA, Marco E, Gilbert HB, Raffaele GP, Brito M, Gimenez M, Moledo LI. Natriuretic effects and changes in renal hemodynamics induced by enalapril in essential hypertension. Drugs. 1985; 30: 149–158.

10.1161/hyp.30.1.140

10.1016/S0140-6736(99)12323-7

10.2337/diacare.21.4.597

10.1001/jama.288.23.2981

10.3317/jraas.2003.026

10.1111/j.1524-6175.2003.02287.x

10.1097/00005344-199002000-00015

10.2337/diacare.22.9.1586

10.1097/00004872-200309000-00027

10.1056/NEJMoa011161

10.1056/NEJMoa011489

10.1161/01.cir.0000024416.33113.0a

10.1016/S0149-2918(02)80016-9

10.2337/diacare.25.2007.S85

10.1016/S0140-6736(02)08089-3

10.1097/00004872-200209000-00035

10.1016/S0140-6736(02)08090-X

Julius S. Long-term potential of angiotensin receptor blockade for cardiovascular protection in hypertension: the VALUE trial. Valsartan Antihypertensive Long-term Use Evaluation. Cardiology. 1999; 91: 8–13.

Ruilope L. Proven benefits of angiotensin receptor blockers in the progression of renal disease. Europ Heart J Suppl. 2003; 5: C9–C12.

10.1007/s00125-002-0935-1

10.1016/S0002-9149(02)02233-6

Thông tin
Thông tin xuất bản

Hypertension

Tập 44 Số 1

12-19

Thông tin tác giả